AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Regeneron Pharmaceuticals Trading Volume Plummets 43.54% to 180th Position
Generated by AI AgentAinvest Market Brief
Tuesday, May 13, 2025 7:42 pm ET1min read
On May 13, 2025,
, Inc. (REGN) experienced a significant decline, with its trading volume reaching $611 million, a 43.54% decrease from the previous day. This placed at the 180th position in terms of trading volume for the day. The stock price of Regeneron also decreased by 0.26%.Regeneron Pharmaceuticals, Inc. is scheduled to participate in the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 1:00 PM ET. Ryan Crowe, the Senior Vice President of Investor Relations, will represent the company at the event. This conference provides a platform for Regeneron to engage with investors and industry experts, potentially influencing market sentiment and investor confidence in the company's future prospects.
Ainvest Market Brief
Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.
Latest Articles
Morning Market Pulse: Trump Trade War Threats and Fed Uncertainty Weigh on Markets
Dec.23 2025
What to Trade Today: Gold and Copper Rally as Biotech and Metals Stocks Offer Volatile Short-Term Gaps
Dec.23 2025
U.S. Corporate Actions | Ticker Changes and Dividend Announcements Highlight Activity
Dec.23 2025
Morning Market Pulse: Trump Housing Overhaul & AI Surge Drive Pre-Market Moves
Dec.22 2025
Morning Market Pulse: Trump’s Federal Pay Raise & Japan’s Policy Shift Drive Pre-Market Moves
Dec.19 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet